Computational Biology consultant Owner/founder of Orlando Data Science, LLC
CT
Civetta Therapeutics
civettatherapeutics.com
Website unreachable since Oct 16, 2026
Civetta Therapeutics develops small molecule drugs that specifically target beta-propeller domains to inhibit cancer cell growth. This approach addresses the need for more effective cancer treatments by focusing on previously untapped molecular targets.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$53MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many cancer cells rely on specific protein-protein interactions mediated by beta-propeller domains for growth and survival. Traditional cancer therapies often lack the specificity to disrupt these interactions effectively, leading to off-target effects and drug resistance. There is a need for more targeted therapies that can selectively inhibit these protein-protein interactions.
Solution
Civetta Therapeutics develops small molecule drugs designed to selectively bind to and inhibit beta-propeller domains, disrupting critical protein-protein interactions within cancer cells. By targeting these previously undruggable domains, the company aims to halt cancer cell growth and proliferation with greater precision. This approach seeks to minimize off-target effects and overcome resistance mechanisms associated with conventional cancer treatments. The selective inhibition of beta-propeller domains offers a novel strategy for addressing unmet needs in cancer therapy.
Target Audience
The primary target audience includes pharmaceutical companies and oncology researchers seeking novel therapeutic approaches for cancer treatment.
Features
- Small molecule drug development targeting beta-propeller domains.
- Selective inhibition of protein-protein interactions essential for cancer cell survival.
- Designed to minimize off-target effects compared to traditional chemotherapies.
- Focus on previously undruggable targets to overcome resistance mechanisms.